SMMT
Summit Therapeutics Inc.Marquee-fund ownership over time
This quarter's activity
New positions opened
Positions exited
None.
Current holders
Sorted by tenure (longest first)| Fund | First disclosed | Held | Entry price | Latest close | Return on entry |
|---|---|---|---|---|---|
| Citadel Advisors re-entered | Q3 2024(8Q snapshot) | 7Q | $0.00 | — | — |
| Two Sigma Investments re-entered | Q3 2024(8Q snapshot) | 7Q | $0.00 | — | — |
| D.E. Shaw re-entered | Q3 2024(8Q snapshot) | 7Q | $0.00 | — | — |
| AQR Capital Management re-entered | Q3 2024(8Q snapshot) | 7Q | $0.00 | — | — |
| Millennium Management re-entered | Q3 2024(8Q snapshot) | 7Q | $0.00 | — | — |
| Point72 Asset Management re-entered | Q3 2025(8Q snapshot) | 3Q | $0.00 | $16 | — |
“Return on entry” is the price-only move from the fund's first disclosure to today — it ignores any adds, trims, or dividends. A fund that built its position over multiple quarters has a true cost basis somewhere between entry price and latest close; this figure is the upper bound.
Past holders
Funds that exited at some point| Fund | Last entry | Exited | Entry → Exit | Return |
|---|---|---|---|---|
| Renaissance Technologies 2× in & out | Q1 2025 | Q2 2025 | — | +0% |
| Maverick Capital 5× in & out | Q1 2024 | Q2 2024 | — | +0% |
| Appaloosa | Q1 2017 | Q1 2019 | — | +0% |
| JANA Partners 2× in & out | Q4 2018 | Q1 2019 | — | +0% |
Insider activity
Form 4 — officers, directors, 10%+ ownersFiled within two business days of each transaction by anyone with material insider status at Summit Therapeutics Inc.. Pair with the holders table above as a sanity check: heavy insider buying alongside marquee-fund accumulation is the strongest accumulation signal; heavy insider selling alongside fund exits is the strongest distribution signal.
30d / 90d windows measured from Jun 4, 2026 — the most recent Form 4 on file — not from today.
- Form 40001055919-26-000005Jun 4, 2026
- Form 40001507650-26-000005Jun 4, 2026
- Form 40001569769-26-000004Jun 4, 2026
- Form 40001890784-26-000003Jan 12, 2026
- Form 40001507650-26-000003Jan 6, 2026
- Form 40001055919-26-000003Jan 6, 2026
- Form 40001507567-26-000003Jan 6, 2026
- Form 40001963544-26-000002Jan 6, 2026
- Form 40001463740-26-000003Jan 6, 2026
- Form 40001441876-26-000002Jan 6, 2026
- Form 40001561736-26-000002Jan 6, 2026
- Form 40001827015-26-000002Jan 6, 2026
- Form 40001963544-25-000004Oct 23, 2025
- Form 40001890784-25-000005Oct 23, 2025
- Form 40001569769-25-000002Oct 23, 2025
Fundamentals
XBRL · Summit Therapeutics Inc.Annual figures sourced directly from Summit Therapeutics Inc.'s 10-K / 10-Q filings via SEC EDGAR XBRL. Latest fiscal year and the year-over-year change, with up to ten years of history.
Recent SEC filings
10-K · 10-Q · 8-K · 13D/G · proxyThe most recent material filings for Summit Therapeutics Inc. — earnings, material events, ownership disclosures, proxy statements. Form 4 insider activity is shown in the panel above.
- 8-KMaterial eventJun 3, 2026
- 8-KMaterial eventJun 1, 2026
- 10-QQuarterly reportApr 30, 2026
- 8-KMaterial eventApr 30, 2026
- DEF 14AProxy statementApr 17, 2026
- 10-KAnnual reportFeb 23, 2026
- 8-KMaterial eventFeb 23, 2026
- 8-KMaterial eventJan 29, 2026
- 8-KMaterial eventJan 12, 2026
- 8-KMaterial eventNov 7, 2025
- 8-KMaterial eventOct 22, 2025
- 10-QQuarterly reportOct 20, 2025
- 8-KMaterial eventOct 20, 2025
- 8-KMaterial eventSep 8, 2025
- 8-KMaterial eventAug 11, 2025
Trade history
Every open→close lifecycle across tracked funds| Fund | Open date | Close date | Open price | Close price / current | Return |
|---|---|---|---|---|---|
| Point72 Asset Management | Q2 2026 | open | $17 | $16 | -5% |
| Two Sigma Investments | Q4 2025 | open | $18 | $16 | -11% |
| Point72 Asset Management | Q3 2025 | Q4 2025 | $0.00 | — | +0% |
| Renaissance Technologies | Q1 2025 | Q2 2025 | $0.00 | — | +0% |
| Citadel Advisors | Q4 2024 | open | $19 | $16 | -18% |
| Citadel Advisors | Q3 2024 | Q2 2025 | $0.00 | — | +0% |
| Two Sigma Investments | Q3 2024 | Q2 2025 | $0.00 | — | +0% |
| D.E. Shaw | Q3 2024 | Q1 2025 | $0.00 | — | +0% |
| D.E. Shaw | Q3 2024 | open | $11 | $16 | +44% |
| AQR Capital Management | Q3 2024 | Q2 2025 | $0.00 | — | +0% |
| AQR Capital Management | Q3 2024 | open | $11 | $16 | +44% |
| Millennium Management | Q3 2024 | Q2 2025 | $0.00 | — | +0% |
| Millennium Management | Q3 2024 | open | $11 | $16 | +44% |
| Renaissance Technologies | Q3 2024 | Q4 2024 | $0.00 | — | +0% |
| Maverick Capital | Q1 2024 | Q2 2024 | $0.00 | — | +0% |
| Maverick Capital | Q2 2021 | Q4 2021 | $0.00 | — | +0% |
| Maverick Capital | Q2 2020 | Q3 2020 | $0.00 | — | +0% |
| JANA Partners | Q4 2018 | Q1 2019 | $0.00 | — | +0% |
| Appaloosa | Q1 2017 | Q1 2019 | $0.00 | — | +0% |
| Maverick Capital | Q4 2016 | Q1 2017 | $0.00 | — | +0% |
| Maverick Capital | Q2 2015 | Q3 2015 | $0.00 | — | +0% |
| JANA Partners | Q2 2015 | Q3 2015 | $0.00 | — | +0% |
- Covers only the 27 marquee funds tracked here, not the full institutional universe. A “0 holders” reading does not mean unowned.
- Heavy funds (Renaissance Technologies, Citadel Advisors, Soros Fund Management, Two Sigma Investments, D.E. Shaw, AQR Capital Management, Millennium Management, Point72 Asset Management) use 8-quarter snapshots, so their pre-2024 history is missing.
- “Current” reflects each fund's most recent 13F — filings lag the actual trade by up to 45 days; positions shown may have changed since.
- Cost = price at the entry filing date. Re-entered positions show the most recent open lot.
- Options, ADRs, and unmapped CUSIPs are excluded from the follower-backtest pipeline that produces these snapshots, so certain holding types won't appear here.